SG11201401043SA - P53 activating peptides - Google Patents

P53 activating peptides

Info

Publication number
SG11201401043SA
SG11201401043SA SG11201401043SA SG11201401043SA SG11201401043SA SG 11201401043S A SG11201401043S A SG 11201401043SA SG 11201401043S A SG11201401043S A SG 11201401043SA SG 11201401043S A SG11201401043S A SG 11201401043SA SG 11201401043S A SG11201401043S A SG 11201401043SA
Authority
SG
Singapore
Prior art keywords
activating peptides
peptides
activating
Prior art date
Application number
SG11201401043SA
Other languages
English (en)
Inventor
Walter Goh
Farid John Ghadessy
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201401043SA priority Critical patent/SG11201401043SA/en
Publication of SG11201401043SA publication Critical patent/SG11201401043SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
SG11201401043SA 2011-09-09 2012-09-10 P53 activating peptides SG11201401043SA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201401043SA SG11201401043SA (en) 2011-09-09 2012-09-10 P53 activating peptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2011065901 2011-09-09
PCT/SG2012/000329 WO2013036208A1 (en) 2011-09-09 2012-09-10 P53 activating peptides
SG11201401043SA SG11201401043SA (en) 2011-09-09 2012-09-10 P53 activating peptides

Publications (1)

Publication Number Publication Date
SG11201401043SA true SG11201401043SA (en) 2014-08-28

Family

ID=54259020

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601840RA SG10201601840RA (en) 2011-09-09 2012-09-10 P53 activating peptides
SG11201401043SA SG11201401043SA (en) 2011-09-09 2012-09-10 P53 activating peptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201601840RA SG10201601840RA (en) 2011-09-09 2012-09-10 P53 activating peptides

Country Status (4)

Country Link
US (1) US9517252B2 (de)
EP (2) EP2753635A4 (de)
SG (2) SG10201601840RA (de)
WO (1) WO2013036208A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
CN103282510A (zh) 2010-08-13 2013-09-04 爱勒让治疗公司 拟肽大环化合物
WO2013036208A1 (en) 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
EP2822572B1 (de) 2012-02-15 2020-06-10 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
US9873718B2 (en) * 2013-05-08 2018-01-23 The Regents Of The University Of California Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
JP6554099B2 (ja) * 2013-08-07 2019-07-31 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． ｐ５３変異体を再活性化することの可能なペプチド
WO2015145432A2 (en) * 2014-03-24 2015-10-01 Yeda Research And Development Co. Ltd. Stabilization of mutant p53 in wild type conformation by proteins of embryonic stem cells
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
JP7072508B2 (ja) * 2016-02-04 2022-05-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用
MX2018009947A (es) 2016-02-19 2019-01-21 Pmv Pharmaceuticals Inc Metodos y composiciones para restablecer la funcion de p53 mutante.
GB201617564D0 (en) 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
EP3724216A1 (de) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Durch stabilisiertes peptid vermittelter zielgerichteter proteinabbau
EP3749678A1 (de) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Zellpermeable, geheftete peptidmodule zur zellulären abgabe
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP7374309B2 (ja) 2019-09-23 2023-11-06 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物
WO2021207598A1 (en) * 2020-04-10 2021-10-14 Aprea Therapeutics, Inc. Combination treatment with an agonist of p53 and a second therapeutic agent
US11938124B2 (en) 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
CA3193261A1 (en) 2020-10-14 2022-04-21 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
WO1998051707A1 (fr) * 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides a structures cycliques et a effet restaurateur d'activite de la proteine p53 sur les mutants de ladite proteine
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
US20100293663A2 (en) 1998-06-16 2010-11-18 Thomas La Rosa Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
EP2197908A2 (de) * 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
US20110214205A1 (en) * 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
WO2013036208A1 (en) 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides

Also Published As

Publication number Publication date
US9517252B2 (en) 2016-12-13
SG10201601840RA (en) 2016-04-28
US20150359843A1 (en) 2015-12-17
EP2753635A1 (de) 2014-07-16
WO2013036208A1 (en) 2013-03-14
EP3444262A2 (de) 2019-02-20
EP2753635A4 (de) 2015-08-12
EP3444262A3 (de) 2019-04-10

Similar Documents

Publication Publication Date Title
HK1243427A1 (zh) 治療肽
SG10201601840RA (en) P53 activating peptides
ZA201309174B (en) Polypeptides
IL233280A0 (en) Cell-penetrating peptides
GB201012651D0 (en) Peptides
ZA201307169B (en) Neuroprotective peptides
EP2753641A4 (de) Neuroprotektive zellpenetrierende peptide
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
HK1209138A1 (en) Peptides
EP2627674A4 (de) Peptide auf egfr-basis
EP2793918A4 (de) Hdc-sign-bindende peptide
GB201204868D0 (en) Peptides
EP2714717A4 (de) Phoenixinpeptide
PT2891663T (pt) Péptidos derivados de psf1
IL228354A0 (en) Neuroprotective peptides
HK1202554A1 (en) Cladosporium peptides
GB201115014D0 (en) Peptides
GB201105653D0 (en) Anti-microbial peptides
AU2011903086A0 (en) Peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
HUE047406T2 (hu) Polipeptidek